Matthew Price is the founder of Promontory Therapeutics. Promontory Therapeutics has raised $74M in total funding. Latest round: Series A.
Matthew Price is the Co-Founder and COO of Promontory Therapeutics, a biotech company in drug development focused on immuno-oncology, specifically small molecule therapies that engage the immune system to kill cancer cells. The company has progressed its programs through preclinical development, three different Phase 1 studies, and is now in the Phase 2 stage. Price is responsible for industry collaborations with Pfizer and Merck KGaA, and a CRADA with the National Cancer Institute.
Full founder directory · Investor directory · Company funding database · Fundraising library